Printer Friendly

Smithkline Beecham obtains United States patent.

Smithkline Beecham Corporation (Philadelphia, PA) has patented TR7 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques. Also disclosed are methods for utilizing TR7 polypeptides and polynucleotides in the design of protocols for the treatment of chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (such as inflammatory bowel disease and psoriasis), transplant rejection, graft versus host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, bone diseases, cancer (such as lymphoproliferative disorders), atherosclerosis, and Alzheimers disease, among others and diagnostic assays for such conditions. (US 6013476)
COPYRIGHT 2000 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Smithkline Beecham obtains United States patent.
Publication:BIOTECH Patent News
Geographic Code:1USA
Date:May 1, 2000
Previous Article:Oxford GlycoSciences files patent application for breast cancer proteins and genes.
Next Article:Boston Scientific announces settlement of all litigation with Guidant.

Related Articles
Aradigm issued new method patent for pulmonary delivery of insulin analogs.
Smithkline Beecham obtains United States patent.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters